# EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

> **NCT03519984** · PHASE1 · TERMINATED · sponsor: **University of Southern California** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- Myelodysplastic/Myeloproliferative Neoplasm
- Philadelphia Chromosome Positive
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Secondary Acute Myeloid Leukemia
- T Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cytarabine
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Recombinant EphB4-HSA Fusion Protein
- **DRUG:** Vincristine Liposomal

## Key facts

- **NCT ID:** NCT03519984
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-09
- **Primary completion:** 2020-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study drug supply issue
- **Last updated:** 2021-11-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519984, "EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03519984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*